View more job listings or post a job
Jazz Pharmaceuticals Head of Toxicology
Dow Development Laboratories Formulation Chemist
Genentech Scientist, DMPK
Pliant Therapeutics, Inc. Associate Director/ Director, Formulation Development
AbVision Inc. Research Scientist (Immunology/Cell Biology, all levels available)
Regulus Therapeutics Senior Research Associate/Scientist, Drug Metabolism and Pharmacokinetics
Aligos Therapeutics Principal Research Scientist, DMPK
Post a job


Physiologically Based Pharmacokinetic (PBPK) Modeling: Fundamentals, Regulatory Guidance & Applications

Speakers: Yuan Chen, Michael Bolger, Karen Rowland Yeo, Susie Zhang, Ying Ou, Venkatesh Pilla Reddy, Ping Zhao
Organizers: Yuan Chen (Genentech), Tracy Chen (Jazz), Snow Ge (Nektar), Ying Ou (BeiGene)
Date: 2019-10-18
Time: 8:45-17:00 Pacific Time
Registration fee (USD): Regular - Full Day: $195; Regular - Morning Only: $125; Regular - Afternoon Only: $125; Academic: $125; For unemployed or students: $35; For vendor-show rep: $35; For major-sponsor rep (incl lunch): $0
Location: SF Bay Area: Foster City Crowne Plaza
Major Sponsor:
Vendor show vendors registered to date: (3)MicroConstants; Pion Inc.; SEKISUI XenoTech
Registration deadline:2019-10-18  (it will close sooner if the seating cap is reached)

About the Topic

Physiologically based pharmacokinetic (PBPK) models have been widely used at various stages of drug product development and regulatory review for different purposes, such as predicting absorption, distribution, metabolism and excretion (ADME), assessing drug-drug interaction (DDI) potentials, providing mechanistic explanation to PK characteristics, and predicting pharmacokinetics (PK) in specific populations.

Morning sessions: 

Physiologically-based Pharmacokinetic Modeling:  Overview of Basic Knowledge and Applications

  1. Overview of Basic Knowledge (Yuan Chen, 25min)

-What is PBPK model, Why PBPK, differences from empirical model

-Components of PBPK model

-Principle of ADME prediction using mechanistic approach

  1. Concept and Application (Karen Rowland Yeo and Michael Bolger)

1)      Prediction of absorption (Michael Bolger, 60 min)

 - Fa /Ka; PK linearity; Food  / PPI effect; Formulation

2)      Prediction of Drug-drug interaction (Karen Rowland Yeo, 90min)

 - CYP-mediated DDI (substrate, inhibition, induction etc)

 - Transporter –mediated DDI (substrate and inhibitor etc.)

3)      Prediction of PK in special populations (Karen Rowland Yeo)

 - PK in organ impaired population; PK in pediatrics; Others

Afternoon Sessions:

Physiologically Based Pharmacokinetic Modeling:  Role in drug development and regulatory filing by case examples

  1. Physiologically Based Pharmacokinetic Modeling in Regulatory Science: An Update From the FDA and overview of PBPK guidance (Susie Zhang, 30min)
  1. Physiologically Based Pharmacokinetic Model Qualification and Reporting procedure for Regulatory Submission: A Consortium Perspective (Yuan Chen, 30min)
  1. PBPK impact on the label of CYP DDI, PPI (absorption), oral contraception (Ying Ou, 45min)
  1. PBPK Modeling and simulation to predict transporter mediated drug-drug interactions: are we there yet? (Venkatesh Pilla Reddy, 45min)
  1. PBPK models for dose recommendation in organ impaired and pediatric population (Ping Zhao, 30min) 

2019-07-26, Generating Efficacious Enzyme Therapeutics based on Knowledge Learned From Biocatalytic Pharmaceutical Manufacture
2019-09-13, Biotransformation and Disposition of Larger Molecules: Peptides, Nucleotides, Proteins, mAbs, and ADCs
2019-10-03, Small-Molecule Bioanalytical Method Validation & Regulated Bioanalysis: Fundamentals, the New FDA Guidance and Regulatory Trends
2019-11-12, Antibody Drug Discovery and Development: Hit Generation, Engineering, Cell-line Development, IND enabling studies, and Biosimilars
2019-12-10, In Vitro Diagnostics, Companion Diagnostics and Precision Medicine
2020-02-11, Drug-Device Combination
2020-05-12, Regulated Large Molecule Bioanalysis: Fundamentals, the New FDA Guidance and Beyond
2020-05-22, No More Undruggables: Unconventional Approaches for Drug Discovery and Design - prodrugs, PROTACS, fragment-based design, directed evolution and beyond
┬ęPharmaceutical & BioScience Society, International; Last Modified: 7/22/2019; Visited: 346; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Pacific BioLabs CRO in Bay Area - PK, toxicology, biocompatibility, analytical chemistry, immunogenicity, biomarker analysis, stability studies, sterility, endotoxin
Hypha Discovery mg-g scale synthesis/purification of CYP/non-CYP metabolites including glucuronides. Plus NEW PolyCYPs kits for in-house synthesis of CYP metabolites.
BIOTECH WEEK BOSTON - Sept. 9-12 Access over 5,000 of the most innovative scientific minds & business leaders in Boston and around the world. Learn More.
UC Davis UC Davis LC/MS Confirmation Supervisor (Lab Rsch Supv 2) Apply Online: UC Davis is an AA/EOE
XCELERATE at Biotech Week Boston Driving the Future of the Life Science Industry. Sept. 11 at BCEC. Learn more.
Submit a Text Ad